DK2061513T3 - Fremgangsmåde til behandling af patienter med hepatitis C - Google Patents

Fremgangsmåde til behandling af patienter med hepatitis C

Info

Publication number
DK2061513T3
DK2061513T3 DK08831728.4T DK08831728T DK2061513T3 DK 2061513 T3 DK2061513 T3 DK 2061513T3 DK 08831728 T DK08831728 T DK 08831728T DK 2061513 T3 DK2061513 T3 DK 2061513T3
Authority
DK
Denmark
Prior art keywords
hepatitis
treatment
patients
procedure
relapsed
Prior art date
Application number
DK08831728.4T
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Robert Orville Ii Ralston
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2061513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK2061513T3 publication Critical patent/DK2061513T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DK08831728.4T 2007-09-14 2008-09-11 Fremgangsmåde til behandling af patienter med hepatitis C DK2061513T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
PCT/US2008/010626 WO2009038663A1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
DK2061513T3 true DK2061513T3 (da) 2011-11-21

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08831728.4T DK2061513T3 (da) 2007-09-14 2008-09-11 Fremgangsmåde til behandling af patienter med hepatitis C

Country Status (18)

Country Link
US (1) US20100226885A1 (da)
EP (2) EP2489369A1 (da)
JP (1) JP2010539165A (da)
CN (1) CN101883590A (da)
AT (1) ATE519503T1 (da)
AU (1) AU2008301981A1 (da)
CA (1) CA2699280A1 (da)
CY (1) CY1112116T1 (da)
DK (1) DK2061513T3 (da)
ES (1) ES2369321T3 (da)
HK (1) HK1129315A1 (da)
HR (1) HRP20110637T1 (da)
MX (1) MX2010002909A (da)
NZ (1) NZ583825A (da)
PL (1) PL2061513T3 (da)
PT (1) PT2061513E (da)
SI (1) SI2061513T1 (da)
WO (1) WO2009038663A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
WO2012151271A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Processes for preparing inhibitors of the hepatitis c virus
CN106166160A (zh) 2011-09-16 2016-11-30 吉利德制药有限责任公司 用于治疗hcv的组合物
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
BR112014012739A8 (pt) * 2011-11-29 2017-06-20 Gilead Pharmasset Llc composições e métodos para o tratamento do vírus da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140363396A1 (en) 2012-02-01 2014-12-11 Kadmon Pharmaceuticals Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AR029337A1 (es) * 1999-03-02 2003-06-25 Schering Corp Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv
DK1385870T3 (da) * 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
RS51394B (en) * 2004-02-27 2011-02-28 Schering Corporation SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
CA2728248A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen

Also Published As

Publication number Publication date
CY1112116T1 (el) 2015-11-04
EP2061513B1 (en) 2011-08-10
EP2061513A1 (en) 2009-05-27
PT2061513E (pt) 2011-10-17
SI2061513T1 (sl) 2011-11-30
EP2489369A1 (en) 2012-08-22
NZ583825A (en) 2012-06-29
AU2008301981A1 (en) 2009-03-26
ATE519503T1 (de) 2011-08-15
ES2369321T3 (es) 2011-11-29
JP2010539165A (ja) 2010-12-16
US20100226885A1 (en) 2010-09-09
CN101883590A (zh) 2010-11-10
PL2061513T3 (pl) 2011-12-30
CA2699280A1 (en) 2009-03-26
HK1129315A1 (en) 2009-11-27
WO2009038663A1 (en) 2009-03-26
HRP20110637T1 (hr) 2011-10-31
MX2010002909A (es) 2010-03-30

Similar Documents

Publication Publication Date Title
DK2061513T3 (da) Fremgangsmåde til behandling af patienter med hepatitis C
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
DK1773999T3 (da) Vaccine til forebyggelse og behandling af HIV-infektion
DE602005022568D1 (de) Ostomie-Vorrichtung
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
DK1814590T3 (da) Behandling af obesitet og beslægtede sygdomme
DK1848415T3 (da) Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
PT2219642E (pt) Componente de silibinina para o tratamento de hepatite
DK1855677T3 (da) 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
HK1096320A1 (en) Apheresis device
DK1809318T3 (da) Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
DK1981506T3 (da) Langtidsbehandling af HIV-infektion med TMC278
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
NO20072285L (no) S-mirtazapin for behandling av hetetokter
EP2224943A4 (en) USE OF A HUMAN ANTIBODY TO NEUTRALIZE HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B INFECTIONS
PL383722A1 (pl) Sposoby i materiały z trans-klomifenem do leczenia bezpłodności u mężczyzn
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding
DK1951274T3 (da) Parapoxvirusser i kombination med klasssiske cytotoksiske kemoterapeutiske midler som biokemoterapi til behandling af cancer
UA90477C2 (ru) Способ лечения гепатита с (варианты)
DK1635820T3 (da) Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt